img-17

1) FDA labeling: The Exablate Neuro is intended for use in the unilateral thalamotomy treatment of idiopathic essential tremor patients with medication-refractory tremor. Patients must be at least age 22.

Disclaimer: The information provided here should not be considered medical advice. Please consult with a qualified physician for diagnosis and treatment. Patient testimonials may not be representative of all treatment outcomes.

Risks associated with any thalamotomy include transient and/or permanent sensory paresthesias, numbness, imbalance, and/or gait disturbance. These events are generally transient and mild or moderate in severity. Risks and adverse events also associated with the Exablate Neuro treatment include brief sonication-related pain, brief sonication-related dizziness and nausea or potential for deep vein thrombosis associated with lengthy time on the treatment bed.